A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC features (adenoBAC).

Trial Profile

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC features (adenoBAC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Bronchiolo-alveolar adenocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Planned end date changed from 1 Nov 2007 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 17 May 2012 New source identified and integrated (OHSU Knight Cancer Institute; SOL12064C).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top